Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Inflammation Research
Erschienen in: Inflammation Research 10/2009

01.10.2009 | Review

Mast cells and eosinophils: the two key effector cells in allergic inflammation

verfasst von: Yael Minai-Fleminger, Francesca Levi-Schaffer

Erschienen in: Inflammation Research | Ausgabe 10/2009

Einloggen, um Zugang zu erhalten

Abstract

The allergic inflammatory response is composed of two main phases—the early and the late. The early phase initiates when an allergen activates the tissue resident mast cell, triggering the release of a variety of granule-stored and newly formed mediators. As the inflammatory response progresses, blood borne inflammatory cells—in particular, eosinophils—are recruited into the inflamed tissue. Eosinophil activation and consequent release and production of several pro-inflammatory mediators results in the late phase reaction. A chronic allergic inflammation always features prominent tissue eosinophilia. In this review, we will discuss the possible channels of communication, both soluble and physical, between mast cells and eosinophils that can occur in the late and chronic stages of allergy. Such interactions, that we have termed “the allergic effector unit”, may modulate the severity and/or duration of the allergic inflammatory reaction.
Literatur
1.
2.
Lawson JA, Senthilselvan A. Asthma epidemiology: has the crisis passed? Curr Opin Pulm Med. 2005;11:79–84.PubMedCrossRef
3.
Williams CM, Galli SJ. The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J Allergy Clin Immunol. 2000;105(5):847–59.
4.
Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature 2008;454:445–54.PubMedCrossRef
5.
Bloemen K, Verstraelen S, Van Den Heuvel R, Witters H, Nelissen I, Schoeters G. The allergic cascade: review of the most important molecules in the asthmatic lung. Immunol Lett. 2007;113:6–18.PubMedCrossRef
6.
Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol. 2007;7:93–104.PubMedCrossRef
7.
Metz M, Grimbaldeston MA, Nakae S, Piliponsky AM, Tsai M, Galli SJ. Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev. 2007;217:304–28.PubMedCrossRef
8.
9.
10.
Bischof RJ, Snibson KJ, Velden JV, Meeusen EN. Immune response to allergens in sheep sensitized to house dust mite. J Inflamm (Lond). 2008;5:16.CrossRef
11.
Bachelet I, Levi-Schaffer F, Mekori YA. Mast cells: not only in allergy. Immunol Allergy Clin North Am. 2006;26:407–25.PubMedCrossRef
12.
Tsai M, Grimbaldeston MA, Yu M, Tam SY, Galli SJ. Using mast cell knock-in mice to analyze the roles of mast cells in allergic responses in vivo. Chem Immunol Allergy. 2005;87:179–97.PubMedCrossRef
13.
Matsumoto M, Kunimitsu S, Wada K, Ikeda M, Keyama A, Kodama H. Mast cell distribution, activation, and phenotype in xanthoma. J Am Acad Dermatol. 2007;56:1006–12.PubMedCrossRef
14.
Prussin C, Metcalfe DD. 5. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2006;117:S450–6.PubMedCrossRef
15.
Roth K, Chen WM, Lin TJ. Positive and negative regulatory mechanisms in high-affinity IgE receptor-mediated mast cell activation. Arch Immunol Ther Exp (Warsz). 2008;56:385–99.CrossRef
16.
Ryan JJ, Kashyap M, Bailey D, Kennedy S, Speiran K, Brenzovich J, et al. Mast cell homeostasis: a fundamental aspect of allergic disease. Crit Rev Immunol. 2007;27:15–32.PubMed
17.
Shelburne CP, Ryan JJ. The role of Th2 cytokines in mast cell homeostasis. Immunol Rev. 2001;179:82–93.PubMedCrossRef
18.
Gelfand EW. Inflammatory mediators in allergic rhinitis. J Allergy Clin Immunol. 2004;114:S135–8.PubMedCrossRef
19.
Jacobsen EA, Ochkur SI, Lee NA, Lee JJ. Eosinophils and asthma. Curr Allergy Asthma Rep. 2007;7:18–26.PubMedCrossRef
20.
Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol. 2007;119:1303–10. quiz 1311–2.PubMedCrossRef
21.
22.
Hogan SP. Recent advances in eosinophil biology. Int Arch Allergy Immunol. 2007;143(Suppl 1):3–14.PubMedCrossRef
23.
Mattes J, Foster PS. Regulation of eosinophil migration and Th2 cell function by IL-5 and eotaxin. Curr Drug Targets Inflamm Allergy. 2003;2:169–74.PubMedCrossRef
24.
Lopez AF, Begley CG, Williamson DJ, Warren DJ, Vadas MA, Sanderson CJ. Murine eosinophil differentiation factor. An eosinophil-specific colony-stimulating factor with activity for human cells. J Exp Med. 1986;163:1085–99.PubMedCrossRef
25.
Rothenberg ME, Pomerantz JL, Owen WF Jr, Avraham S, Soberman RJ, Austen KF, et al. Characterization of a human eosinophil proteoglycan, and augmentation of its biosynthesis and size by interleukin 3, interleukin 5, and granulocyte/macrophage colony stimulating factor. J Biol Chem. 1988;263:13901–8.PubMed
26.
Nerlov C, Graf T. PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev. 1998;12:2403–12.PubMedCrossRef
27.
Eliashar R, Levi-Schaffer F. The role of the eosinophil in nasal diseases. Curr Opin Otolaryngol Head Neck Surg. 2005;13:171–5.PubMedCrossRef
28.
Temkin V, Kantor B, Weg V, Hartman ML, Levi-Schaffer F. Tryptase activates the mitogen-activated protein kinase/activator protein-1 pathway in human peripheral blood eosinophils, causing cytokine production and release. J Immunol. 2002;169:2662–9.PubMed
29.
Adamko D, Odemuyiwa SO, Moqbel R. The eosinophil as a therapeutic target in asthma: beginning of the end, or end of the beginning? Curr Opin Pharmacol. 2003;3:227–32.PubMedCrossRef
30.
El Gazzar M, El Mezayen R, Nicolls MR, Marecki JC, Dreskin SC. Downregulation of leukotriene biosynthesis by thymoquinone attenuates airway inflammation in a mouse model of allergic asthma. Biochim Biophys Acta. 2006;1760:1088–95.PubMed
31.
Ohnishi H, Miyahara N, Gelfand EW. The role of leukotriene B(4) in allergic diseases. Allergol Int. 2008;57.
32.
Landgraf MA, Landgraf RG, Carvalho MH, Fortes ZB. Modulation of lung allergic inflammation and malnutrition. Neuroimmunomodulation 2008;15:194–206.PubMedCrossRef
33.
Hartman M, Piliponsky AM, Temkin V, Levi-Schaffer F. Human peripheral blood eosinophils express stem cell factor. Blood 2001;97:1086–91.PubMedCrossRef
34.
O’Donnell MC, Ackerman SJ, Gleich GJ, Thomas LL. Activation of basophil and mast cell histamine release by eosinophil granule major basic protein. J Exp Med. 1983;157:1981–91.PubMedCrossRef
35.
Piliponsky AM, Gleich GJ, Nagler A, Bar I, Levi-Schaffer F. Non-IgE-dependent activation of human lung- and cord blood-derived mast cells is induced by eosinophil major basic protein and modulated by the membrane form of stem cell factor. Blood 2003;101:1898–904.PubMedCrossRef
36.
Piliponsky AM, Pickholtz D, Gleich GJ, Levi-Schaffer F. Human eosinophils induce histamine release from antigen-activated rat peritoneal mast cells: a possible role for mast cells in late-phase allergic reactions. J Allergy Clin Immunol. 2001;107:993–1000.PubMedCrossRef
37.
Puxeddu I, Ribatti D, Crivellato E, Levi-Schaffer F. Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol. 2005;116:531–6.PubMedCrossRef
38.
Shakoory B, Fitzgerald SM, Lee SA, Chi DS, Krishnaswamy G. The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res. 2004;24:271–81.PubMedCrossRef
39.
Bischoff SC, Dahinden CA. c-kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med. 1992;175:237–44.PubMedCrossRef
40.
Dastych J, Metcalfe DD. Stem cell factor induces mast cell adhesion to fibronectin. J Immunol. 1994;152:213–9.PubMed
41.
Meininger CJ, Yano H, Rottapel R, Bernstein A, Zsebo KM, Zetter BR. The c-kit receptor ligand functions as a mast cell chemoattractant. Blood 1992;79:958–63.PubMed
42.
Hermes B, Welker P, Feldmann-Boddeker I, Kruger-Krasagakis S, Hartmann K, Zuberbier T, et al. Expression of mast cell growth modulating and chemotactic factors and their receptors in human cutaneous scars. J Invest Dermatol. 2001;116:387–93.PubMedCrossRef
43.
Tam SY, Tsai M, Yamaguchi M, Yano K, Butterfield JH, Galli SJ. Expression of functional TrkA receptor tyrosine kinase in the HMC-1 human mast cell line and in human mast cells. Blood 1997;90:1807–20.PubMed
44.
Zheutlin LM, Ackerman SJ, Gleich GJ, Thomas LL. Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. J Immunol. 1984;133:2180–5.PubMed
45.
Patella V, de Crescenzo G, Marino I, Genovese A, Adt M, Gleich GJ, et al. Eosinophil granule proteins activate human heart mast cells. J Immunol. 1996;157:1219–25.PubMed
46.
Ellyard JI, Simson L, Bezos A, Johnston K, Freeman C, Parish CR. Eotaxin selectively binds heparin. An interaction that protects eotaxin from proteolysis and potentiates chemotactic activity in vivo. J Biol Chem. 2007;282:15238–47.PubMedCrossRef
47.
Temkin V, Aingorn H, Puxeddu I, Goldshmidt O, Zcharia E, Gleich GJ, et al. Eosinophil major basic protein: first identified natural heparanase-inhibiting protein. J Allergy Clin Immunol. 2004;113:703–9.PubMedCrossRef
48.
Levi-Schaffer F, Temkin V, Malamud V, Feld S, Zilberman Y. Mast cells enhance eosinophil survival in vitro: role of TNF-alpha and granulocyte-macrophage colony-stimulating factor. J Immunol. 1998;160:5554–62.PubMed
49.
Hoenstein R, Admon D, Solomon A, Norris A, Moqbel R, Levi-Schaffer F. Interleukin-2 activates human peripheral blood eosinophils. Cell Immunol. 2001;210:116–24.PubMedCrossRef
50.
Temkin V, Levi-Schaffer F. Mechanism of tumour necrosis factor alpha mediated eosinophil survival. Cytokine 2001;15:20–6.PubMedCrossRef
51.
Temkin V, Pickholtz D, Levi-Schaffer F. Tumor necrosis factors in a murine model of allergic peritonitis: effects on eosinophil accumulation and inflammatory mediators’ release. Cytokine 2003;24:74–80.PubMedCrossRef
52.
Liu LY, Bates ME, Jarjour NN, Busse WW, Bertics PJ, Kelly EA. Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF-alpha. J Immunol. 2007;179:4840–8.PubMed
53.
Malaviya R, Ikeda T, Ross E, Abraham SN. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 1996;381:77–80.PubMedCrossRef
54.
Takafuji S, Tadokoro K, Ito K, Nakagawa T. Release of granule proteins from human eosinophils stimulated with mast-cell mediators. Allergy 1998;53:951–6.PubMedCrossRef
55.
Wong CK, Ng SS, Lun SW, Cao J, Lam CW. Signalling mechanisms regulating the activation of human eosinophils by mast-cell-derived chymase: implications for mast cell-eosinophil interaction in allergic inflammation. Immunology 2009;126(4):579–87.
56.
Vliagoftis H, Lacy P, Luy B, Adamko D, Hollenberg M, Befus D, et al. Mast cell tryptase activates peripheral blood eosinophils to release granule-associated enzymes. Int Arch Allergy Immunol. 2004;135:196–204.PubMedCrossRef
57.
Boyce JA. Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. Immunol Rev. 2007;217:168–85.PubMedCrossRef
58.
Saban MR, Saban R, Bjorling D, Haak-Frendscho M. Involvement of leukotrienes, TNF-alpha, and the LFA-1/ICAM-1 interaction in substance P-induced granulocyte infiltration. J Leukoc Biol. 1997;61:445–51.PubMed
59.
Schain F, Tryselius Y, Sjoberg J, Porwit A, Backman L, Malec M, et al. Evidence for a pathophysiological role of cysteinyl leukotrienes in classical Hodgkin lymphoma. Int J Cancer. 2008;123:2285–93.PubMedCrossRef
60.
Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989–90.PubMedCrossRef
61.
Sehmi R, Wardlaw AJ, Cromwell O, Kurihara K, Waltmann P, Kay AB. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood 1992;79:2952–9.PubMed
62.
Bandeira-Melo C, Weller PF. Eosinophils and cysteinyl leukotrienes. Prostaglandins Leukot Essent Fatty Acids. 2003;69:135–43.PubMedCrossRef
63.
Bandeira-Melo C, Bozza PT, Weller PF. The cellular biology of eosinophil eicosanoid formation and function. J Allergy Clin Immunol. 2002;109:393–400.PubMedCrossRef
64.
Weller PF. Lipid, peptide and cytokine mediators elaborated by eosinophils. In: Smith JH, Cook RM, editors. Immunopharmacology of eosinophils. The Handbook of Immunopharmacology. London: Academic Press; 1993. p. 25–42.
65.
Kaneko I, Suzuki K, Matsuo K, Kumagai H, Owada Y, Noguchi N, et al. Cysteinyl leukotrienes enhance the degranulation of bone marrow-derived mast cells through the autocrine mechanism. Tohoku J Exp Med. 2009;217:185–91.PubMedCrossRef
66.
Bandeira-Melo C, Woods LJ, Phoofolo M, Weller PF. Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion. J Exp Med. 2002;196:841–50.PubMedCrossRef
67.
Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999;285:221–7.PubMedCrossRef
68.
Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 1998;395:82–6.PubMedCrossRef
69.
Kashiwakura J, Yokoi H, Saito H, Okayama Y. T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsillar and lung-cultured mast cells. J Immunol. 2004;173:5247–57.PubMed
70.
Nelson CM, Chen CS. Cell-cell signaling by direct contact increases cell proliferation via a PI3 K-dependent signal. FEBS Lett. 2002;514:238–42.PubMedCrossRef
71.
Dayer JM, Burger D. Cytokines and direct cell contact in synovitis: relevance to therapeutic intervention. Arthritis Res. 1999;1:17–20.PubMedCrossRef
72.
Malaviya R, Gao Z, Thankavel K, van der Merwe PA, Abraham SN. The mast cell tumor necrosis factor alpha response to FimH-expressing Escherichia coli is mediated by the glycosylphosphatidylinositol-anchored molecule CD48. Proc Natl Acad Sci USA. 1999;96:8110–5.PubMedCrossRef
73.
Brill A, Baram D, Sela U, Salamon P, Mekori YA, Hershkoviz R. Induction of mast cell interactions with blood vessel wall components by direct contact with intact T cells or T cell membranes in vitro. Clin Exp Allergy. 2004;34:1725–31.PubMedCrossRef
74.
Inamura N, Mekori YA, Bhattacharyya SP, Bianchine PJ, Metcalfe DD. Induction and enhancement of Fc(epsilon)RI-dependent mast cell degranulation following coculture with activated T cells: dependency on ICAM-1- and leukocyte function-associated antigen (LFA)-1-mediated heterotypic aggregation. J Immunol. 1998;160:4026–33.PubMed
75.
Salamon P, Shoham NG, Gavrieli R, Wolach B, Mekori YA. Human mast cells release Interleukin-8 and induce neutrophil chemotaxis on contact with activated T cells. Allergy 2005;60:1316–9.PubMedCrossRef
76.
Salamon P, Shoham NG, Puxeddu I, Paitan Y, Levi-Schaffer F, Mekori YA. Human mast cells release oncostatin M on contact with activated T cells: possible biologic relevance. J Allergy Clin Immunol. 2008;121:448–455. e5.PubMedCrossRef
77.
Stopfer P, Mannel DN, Hehlgans T. Lymphotoxin-beta receptor activation by activated T cells induces cytokine release from mouse bone marrow-derived mast cells. J Immunol. 2004;172:7459–65.PubMed
78.
Caruso RA, Fedele F, Zuccala V, Fracassi MG, Venuti A. Mast cell and eosinophil interaction in gastric carcinomas: ultrastructural observations. Anticancer Res. 2007;27:391–4.PubMed
79.
Piazuelo MB, Camargo MC, Mera RM, Delgado AG, Peek RM Jr, Correa H, et al. Eosinophils and mast cells in chronic gastritis: possible implications in carcinogenesis. Hum Pathol. 2008;39:1360–9.PubMedCrossRef
80.
Beil WJ, McEuen AR, Schulz M, Wefelmeyer U, Kraml G, Walls AF, et al. Selective alterations in mast cell subsets and eosinophil infiltration in two complementary types of intestinal inflammation: ascariasis and Crohn’s disease. Pathobiology 2002;70:303–13.PubMedCrossRef
81.
Bachelet I, Munitz A, Mankutad D, Levi-Schaffer F. Mast cell costimulation by CD226/CD112 (DNAM-1/Nectin-2): a novel interface in the allergic process. J Biol Chem. 2006;281:27190–6.PubMedCrossRef
82.
Bachelet I, Munitz A, Moretta A, Moretta L, Levi-Schaffer F. The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. J Immunol. 2005;175:7989–95.PubMed
83.
Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 1996;4:573–81.PubMedCrossRef
84.
Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003;198:557–67.PubMedCrossRef
85.
Pende D, Bottino C, Castriconi R, Cantoni C, Marcenaro S, Rivera P, et al. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol. 2005;42:463–9.PubMedCrossRef
86.
Munitz A, Bachelet I, Fraenkel S, Katz G, Mandelboim O, Simon HU, et al. 2B4 (CD244) is expressed and functional on human eosinophils. J Immunol. 2005;174:110–8.PubMed
87.
Munitz A, Bachelet I, Eliashar R, Khodoun M, Finkelman FD, Rothenberg ME, et al. CD48 is an allergen and IL-3-induced activation molecule on eosinophils. J Immunol. 2006;177:77–83.PubMed
88.
Forbes E, Hulett M, Ahrens R, Wagner N, Smart V, Matthaei KI, et al. ICAM-1-dependent pathways regulate colonic eosinophilic inflammation. J Leukoc Biol. 2006;80:330–41.PubMedCrossRef
89.
Fox CC, Jewell SD, Whitacre CC. Rat peritoneal mast cells present antigen to a PPD-specific T cell line. Cell Immunol. 1994;158:253–64.PubMedCrossRef
90.
Guo CB, Kagey-Sobotka A, Lichtenstein LM, Bochner BS. Immunophenotyping and functional analysis of purified human uterine mast cells. Blood 1992;79:708–12.PubMed
91.
Munitz A, Bachelet I, Eliashar R, Moretta A, Moretta L, Levi-Schaffer F. The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils. Blood 2006;107:1996–2003.PubMedCrossRef
92.
Stern M, Savill J, Haslett C. Human monocyte-derived macrophage phagocytosis of senescent eosinophils undergoing apoptosis. Mediation by alpha v beta 3/CD36/thrombospondin recognition mechanism and lack of phlogistic response. Am J Pathol. 1996;149:911–21.PubMed
93.
Castells MC, Klickstein LB, Hassani K, Cumplido JA, Lacouture ME, Austen KF, et al. gp49B1-alpha(v)beta3 interaction inhibits antigen-induced mast cell activation. Nat Immunol. 2001;2:436–42.PubMed
94.
Daigle I, Simon HU. Alternative functions for TRAIL receptors in eosinophils and neutrophils. Swiss Med Wkly. 2001;131:231–7.PubMed
95.
Berent-Maoz B, Piliponsky AM, Daigle I, Simon HU, Levi-Schaffer F. Human mast cells undergo TRAIL-induced apoptosis. J Immunol. 2006;176:2272–8.PubMed
96.
Berent-Maoz B, Salemi S, Mankuta D, Simon HU, Levi-Schaffer F. TRAIL mediated signaling in human mast cells: the influence of IgE-dependent activation. Allergy 2008;63:333–40.PubMedCrossRef
Metadaten
Titel
Mast cells and eosinophils: the two key effector cells in allergic inflammation
verfasst von
Yael Minai-Fleminger
Francesca Levi-Schaffer
Publikationsdatum
01.10.2009
Verlag
SP Birkhäuser Verlag Basel
Erschienen in
Inflammation Research / Ausgabe 10/2009
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-009-0042-6

Weitere Artikel der Ausgabe 10/2009

Inflammation Research 10/2009 Zur Ausgabe

Original Research Paper

Lipopolysaccharide from Escherichia coli prevents indomethacin-induced gastric damage in rats: role of non-protein sulfhydryl groups and leukocyte adherence

Original Research Paper

Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions

Original Research Paper

Pro-inflammatory activity in rats of thiocyanate, a metabolite of the hydrocyanic acid inhaled from tobacco smoke

Review

Epigenetics and periodontal disease: future perspectives

Original Research Paper

Evaluation of the inflammatory response in sera from acute ischemic stroke patients by measurement of IL-2 and IL-10

Original Research Paper

Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise